NeuroVive Pharmaceutical AB Market cap
What is the Market cap of NeuroVive Pharmaceutical AB?
The Market cap of NeuroVive Pharmaceutical AB is $17.34M
What is the definition of Market cap?
Market capitalization is the market value at a point in time of the shares outstanding of a publicly traded company, being equal to the share price at that point of time times the number of shares outstanding.
= outstanding shares * previous day’s close
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Market cap of companies in the Health Care sector on OTC compared to NeuroVive Pharmaceutical AB
What does NeuroVive Pharmaceutical AB do?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Companies with market cap similar to NeuroVive Pharmaceutical AB
- Boill Healthcare has Market cap of $17.30M
- Astrotech Corp has Market cap of $17.31M
- China Netcom Technology has Market cap of $17.31M
- Kingfisher Mining has Market cap of $17.32M
- Castle Minerals has Market cap of $17.33M
- Grace Wine has Market cap of $17.34M
- NeuroVive Pharmaceutical AB has Market cap of $17.34M
- Lexagene has Market cap of $17.34M
- The Indian Card Clothing has Market cap of $17.35M
- Lasa Supergenerics has Market cap of $17.35M
- Scorpion Minerals has Market cap of $17.36M
- Widepoint Corp has Market cap of $17.36M
- Eagle Ride Investment has Market cap of $17.37M